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Abstract
Background: NF-κB is a master gene regulator involved in plethora of biological processes, including lymphocyte
activation and proliferation. Reversible ubiquitinylation of key adaptors is required to convey the optimal activation
of NF-κB. However the deubiquitinylases (DUBs), which catalyze the removal of these post-translational
modifications and participate to reset the system to basal level following T-Cell receptor (TCR) engagement
continue to be elucidated.
Findings: Here, we performed an unbiased siRNA library screen targeting the DUBs encoded by the human
genome to uncover new regulators of TCR-mediated NF-κB activation. We present evidence that knockdown of
Ubiquitin-Specific Protease 34 (USP34) selectively enhanced NF-κB activation driven by TCR engagement, similarly
to siRNA against the well-characterized DUB cylindromatosis (CYLD). From a molecular standpoint, USP34 silencing
spared upstream signaling but led to a more pronounced degradation of the NF-κB inhibitor IκBα, and culminated
with an increased DNA binding activity of the transcription factor.
Conclusions: Collectively, our data unveils USP34 as a new player involved in the fine-tuning of NF-κB upon TCR
stimulation.
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Findings
Nuclear factor-κB (NF-κB) transcription factors initiate
transcription of genes essential for mounting an adequate
immune response [1]. Ubiquitously expressed NF-κB
heterodimers of Rel family proteins are normally seques-
tered in the cytosol of the cells by Inhibitors of NF-κB
(IκBs) proteins [2]. In lymphocytes, the ligation of anti-
gen receptors assembles the so-called CBM complex that
consists of the scaffold CARMA1 and the heterodimer
BCL10/MALT1 [3]. The CBM microenvironment drives
oligomerized BCL10 and MALT1 to undergo K63-linked
non-degradative ubiquitinylation [4-7]. This authorizes
the recruitment and activation of the IκB kinase (IKK)
complex that comprises two catalytic subunits (IKKα and
IKKβ) and a regulatory subunit (NEMO, also called
IKKγ) [8]. IKK phosphorylation of IκBs precipitates their
K48-linked ubiquitinylation and proteasomal elimination,
and thereby allows NF-κB to translocate to the nucleus
where it binds DNA and initiates transcription [8].
NF-κB-dependent neosynthesis of IκBs subsequently
drives NF-κB to shuttle back to the cytosol [1]. Although
reversible ubiquitinylation processes are central for
T-cell receptor-(TCR)-mediated NF-κB activation, the
deubiquitinylases (DUBs) in charge of trimming these
poly-ubiquitin chains to ensure optimal signaling, as
well as to reset the system to basal levels remain poorly
defined [9]. Thus far, two DUBs, namely cylindromatosis
(CYLD) and A20 (also known as TNFAIP3), were demon-
strated to negatively regulate antigen receptor signaling
[9,10]. Herein, we provide evidence that Ubiquitin-Specific
Protease 34 (USP34) also contributes to the fine-tuning of
NF-κB upon TCR engagement.
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To identify additional negative regulators of TCR-
mediated NF-κB activation, we conducted a siRNA library
screen against 98 DUBs through a gene reporter luciferase
assay in Jurkat T cells stimulated with either anti-CD3 and
anti-CD28 antibodies or PMA plus ionomycin to mimic
TCR engagement (Figure 1A and Additional files 1 and 2).
As expected, CYLD silencing led to an enhanced NF-κB
activity upon TCR stimulation (Figure 1A). Furthermore,
this screening also uncovered siRNA sequences specific
for USP34 that potentiated NF-κB activation with a
similar magnitude to CYLD siRNA (Figure 1A). USP34
encompasses a 404 kDa protein with a central catalytic
domain [11]. However, little is known about this DUB,
albeit it was previously linked to the Wnt developmental
signaling pathway [12]. Subcellular fractionation experi-
ments showed that USP34 was essentially distributed in
the cytosol of cells regardless of TCR stimulation, and
was notably absent from the nucleus and organelles
(Figure 1B and Additional file 3A). We next verified by
immunoblot that CYLD and USP34 endogenous levels
were efficiently decreased by their respective siRNA
sequences (Figure 1C). Of note, an additional siRNA
duplex specific for USP34 was also included to reinforce
our initial findings (named sequence 3). Consistent with
the primary screening, NF-κB reporter activity was similarly
boosted upon TCR stimulation in USP34- and CYLD-
silenced Jurkat when compared to control non-targeting
siRNA transfected cells (Figure 1D and E). As a conse-
quence, the levels of the NF-κB targets NFKBIA (IκBα),
interleukin-2 (IL-2) and TNFα, as measured by RT-PCR
were increased in USP34-knocked down cells (Figure 1F).
Accordingly, downstream IL-2 secretion was enhanced in
supernatants of USP34-silenced cells (Figure 1G). Finally,
ectopic expression of a plasmid encoding for the catalytic
domain of USP34 (USP34-CD [13]) markedly dampened
TCR-mediated NF-κB activity (Figure 1H). Because
USP34-CD is a large segment (383 amino acids), it is
possible that in addition to the catalytic domain, it also
comprises a domain required for the binding to its
partners to regulate NF-κB in lymphocytes. Collectively,
Figure 1 Identification of USP34 as a negative regulator of TCR-mediated NF-κB activation. (A) NF-κB reporter luciferase assay screen of a
siRNA library targeting 98 DUBs (2 siRNA/target) in Jurkat T lymphocytes stimulated with 20 ng.ml-1 PMA plus 300 ng.ml-1 ionomycin
(P/I, top panel), or with 0.5 μg.ml-1 anti-CD3 and anti-CD28 (bottom panel). Fold activation compared to non-targeting (n.t.) siRNA-treated cells is
shown. Green and red histograms indicate siRNA against USP34 and CYLD, respectively. (B) Nuclear (Nucl.) and cytosolic (Cyt.) fractions from
Jurkat T cells stimulated with P/I as in (A) for 0 and 15 min were analyzed by immunoblot. PARP and tubulin served as loading and purity
controls for nucleus and cytosol, respectively. Molecular weight markers (M.W.) are indicated. (C) Lysates from Jurkat cells transfected for four days
with siRNA against CYLD, USP34 (three individual sequences), or with control n.t. siRNA were analyzed by immunoblot as indicated. (D and E)
NF-κB reporter luciferase assay (mean ± S.D. of triplicate experiments) of n.t.-, CYLD- or USP34-silenced Jurkat cells stimulated as in (A). RLU,
Relative Light Units; Unst, unstimulated cells. (F) Cells as in (C) were stimulated with 20 ng.ml-1 PMA plus 300 ng.ml-1 ionomycin (P/I) for 1 and
2 hours. mRNA levels of NFKBIA (IκBα), IL-2, TNFα, and ACTIN were measured by RT-PCR. (G) Enzyme-Linked ImmunoSorbent Assay (ELISA) of IL-2
secreted in the supernatant of Jurkat treated as in (C) and stimulated with P/I. (H) NF-κB reporter luciferase assay of Jurkat cells transfected with
the catalytic domain of USP34 (V5-tagged USP34-CD) or with a control empty vector (EV) and stimulated as indicated. Histograms represent
mean ± S.D. of triplicate experiments. Inset blot shows USP34-CD expression when overexpressed in HEK293T cells.
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Figure 2 Knockdown of USP34 selectively potentiates NF-κB activation. (A) NFAT reporter luciferase assay (mean ± S.D. of triplicate
experiments) of Jurkat cells transfected with control non-targeting (n.t.) or USP34 siRNA and stimulated with 0, 0.1, 0.5, and 1 μg.ml-1 anti-CD3
and anti-CD28 antibodies (αCD3/28). RLU, Relative Light Units. (B) n.t.- and USP34-silenced Jurkat cells were stimulated with 20 ng.ml-1 PMA plus
300 ng.ml-1 ionomycin (P/I) for 0, 7.5, 15, 30 and 60 min. Cell extracts were prepared and analyzed by immunoblot as indicated. Molecular weight
markers (M.W.) are shown. (C) Cells as in (B) were stimulated with 1 μg.ml-1 anti-CD3 and anti-CD28 antibodies. Cell extracts were prepared and
general tyrosine phosphorylation pattern (P-Tyr) was evaluated by immunoblot. GAPDH served as a loading control. (D) NF-κB reporter luciferase
assay of Jurkat cells transfected as in (A) and stimulated with 10 ng.ml-1 PMA plus 300 ng.ml-1 ionomycin (P/I), with 10 ng.ml-1 TNFα, or with
40 μM etoposide (VP16). Shown is the mean ± S.D. of triplicate experiments. Unst, unstimulated.
Figure 3 Silencing of USP34 enhances IκBα degradation and NF-κB binding to DNA. Jurkat cells were transfected with non-targeting- (n.t.)
or USP34-targeting siRNA for 72-96 h. (A) Lysates from cells stimulated with 40 ng.ml-1 PMA plus 300 ng.ml-1 ionomycin (P/I) for 0, 10, 30 and
60 min were analyzed by immunoblot as indicated. M.W., molecular weight markers. (B) NF-κB binding to DNA was assessed on nuclear extracts
from cells stimulated as in (A) for the indicated time by non-radioactive electrophoretic mobility shift assays (EMSA) using biotin-labeled κB
element DNA sequence. Note that DNA:p65 complexes were chased away with a cold probe, and were shifted when a p65 antibody was added.
(C) Nuclear and cytoplasmic extracts from cells stimulated as in (A) were analyzed by immunoblot as indicated. GAPDH and PARP served as
loading controls. (D) Lysates from cells stimulated as in (A) were assessed by immunoblot as indicated.
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our data suggest that USP34 is a cytosolic protein,
which functions as a negative regulator of NF-κB upon
TCR engagement.
In addition to NF-κB, TCR ligation kindles various signal-
ing pathways including Nuclear factor of activated T-cells
(NFAT) and the Mitogen-activated protein kinase (MAPK)
Extracellular signal-regulated kinases (ERK) [14]. Gene
reporter assays showed only modest increase in NFAT
activation in USP34-silenced when compared to control
cells (Figure 2A). Furthermore, ERK phosphorylation
occurred normally without USP34 (Figure 2B). Keeping
with this, no overt change in the general pattern of tyrosine
phosphorylation was observed upon TCR stimulation,
further arguing against a general impairment of TCR
signaling in the absence of USP34 (Figure 2C). We next
investigated whether USP34 also curtailed NF-κB activity
emanating from TCR-autonomous signaling triggers. To
this end, USP34-silenced Jurkat cells were stimulated
with the cytokine TNFα or with the genotoxic stress
agent etoposide that functions via an unconventional
ATM/PIASy/Sumoylated-NEMO axis [15]. Paralleling
the situation with TCR, knocking down USP34 markedly
increased NF-κB in cells treated with TNFα or etoposide
(Figure 2D). Supporting previous studies with CYLD-
deficient cells [10,16], CYLD silencing in Jurkat cells also
increased TNFα- and etoposide-mediated NF-κB activation
(Additional file 4). Combined, these results indicate that
USP34 shares some functional similarities with CYLD and
selectively targets the NF-κB signaling pathway.
To gain insights on the signaling basis for the exacerbated
NF-κB activity in USP34-depleted cells, we first examined
BCL10 and MALT1 ubiquitinylation status since it governs
the strength of TCR-mediated NF-κB activation [4-6].
BCL10 ubiquitinylation, which can be assessed in fractions
enriched with heavy membranes [17], remained unchanged
without USP34 (Additional file 3A). Moreover, pull-
down of CK1α to precipitate the CBM complex [7,17],
showed similar amounts of ubiquitinylated MALT1 bound
in both control- and USP34-siRNA transfected cells
(Additional file 3B). Keeping with this, BCL10 associ-
ation to CARMA1 occurred normally without USP34
(Additional file 3C). We finally evaluated the impact of
USP34 on the phosphorylation of IKK, which reflects
its activation [8]. IKK phosphorylation was not exacerbated
in those cells, and rather appeared slightly decreased
(Figure 3A, and Additional file 3D). Although puzzling,
this might result from a feedback loop triggered by
enhanced NF-κB. We next assessed directly NF-κB DNA
binding activity. Consistent with the gene reporter assays,
more active NF-κB-DNA complexes were detected in
nuclear extracts from TCR stimulated cells when USP34
was silenced (Figure 3B). Although no obvious difference
in NF-κB subunit p65 translocation into the nucleus was
detected, the degradation of the primary NF-κB inhibitor
IκBα was more pronounced in cytosolic fractions from
USP34-silenced cells when compared to control cells
(Figure 3C). Accordingly, IκBα degradation was also
prolonged or more dramatic in lysates from cells transfected
with USP34 siRNA even on longer time points up to 3 hours
(Figure 3D). Hence, our results suggest that USP34 likely
functions downstream of the CBM-IKK nexus to enhance
NF-κB activation.
Almost 100 DUBs were identified in the human genome
and yet, only a few have been ascribed a function [11]. As
for TCR signaling, the well studied A20 and CYLD thwart
NF-κB at different levels [10]. CYLD targets and inhibits
the ubiquitin-dependent IKKβ kinase TAK1 and therefore
prevents aberrant lymphocyte activation [18,19], while A20
dampens NF-κB activity by trimming K63-ubiquitin chains
attached to MALT1 [20,21]. Our study now unveils USP34
as an additional negative regulator of NF-κB in lympho-
cytes. How USP34 tempers NF-κB activity remains unclear.
In contrast to CYLD and A20, which target apical signaling
[18,20], USP34 rather seems to function downstream of the
IKK complex. Given that USP34 does not bind to the
NF-κB core components (our unpublished results), we
favor a model in which USP34 impacts on the activity of
a cytosolic co-activator to ensure IκBα fine-tuning
[22,23]. Alternatively, USP34 might also intervene in
other checkpoints to control NF-κB signal outcome and
intensity such as post-translational modifications, nuclear
shift, or DNA three-dimensional structure [22,24,25].
Nevertheless, our data illustrates how various layers of
control cooperate to ensure the fine-tuning of NF-κB
following engagement of the TCR.
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and TNFα-mediated NF-κB activation.
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